EMR cumulative indigenous measles/rubella case counts and surveillance indicators
Between 01/01/2017 and 30/04/2017

| Country | Measles case finding report |  |  |  |  |  |  | Rubella case finding report |  |  |  |  |  | Measl <br> es <br> incide <br> nce <br> 11000, <br> 000 <br> $*$ | Rubel <br> la <br> incide <br> nce <br> 11000, <br> 000 <br> $* *$ | $\begin{gathered} \text { Report } \\ \text { ing } \\ \text { rate } \\ * * * \end{gathered}$ | Indicators : target $\geq 80 \%$ |  |  |  |  | Last Date reported | Genotypes reported |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Total suspecte d cases for M/R | specimen <br> s tested for measles | Measles Lab confirm ed | Measles EpiLinked | Measles clinically compatib le | Total measle s | Measles discarde d cases | specim <br> ens <br> tested <br> for <br> rubella | $\begin{array}{c\|} \hline \text { Rubell } \\ \text { a lab } \\ \text { confir } \\ \text { med } \end{array}$ | $\begin{array}{\|c\|} \hline \text { Rube } \\ \text { IIa } \\ \text { Epi- } \\ \text { Link } \\ \text { ed } \end{array}$ | Rube Ila clinic ally | $\begin{gathered} \hline \text { Total } \\ \text { Rubell } \\ \text { a } \end{gathered}$ | Rubella discarde d cases |  |  |  | suspects tested for measles | cases with complete investigati on | specimens recieved at the lab within 5days | specime ns with adequat e condition | results reported back within 4days |  |  |
| Afghanistan | 1245 | 1245 | 817 | 0 | 0 | 817 | 428 | 423 | 36 | 0 | 0 | 36 | 387 | 25.31 | 1.12 | 1.21 | 100\% |  | 56\% | 98\% | 98\% | 30/04/2017 |  |
| Bahrain | 192 | 192 | 0 | 0 | 0 | 0 | 192 | 192 | 0 | 0 | 0 | 0 | 192 | 0.00 | 0.00 | 15.55 | 100\% | 100\% | 100\% | 100\% | 99\% | 30/04/2017 |  |
| Iran | 2157 | 2100 | 42 | 1 | 4 | 47 | 2110 | 2100 | 4 | 0 | 0 | 4 | 2096 | 0.60 | 0.05 | 2.68 | 97\% | 100\% | 91\% | 100\% | 93\% | 30/04/2017 | B3 |
| Iraq | 153 | 71 | 1 | 0 | 0 | 1 | 152 | 147 | 2 | 0 | 0 | 2 | 145 | 0.03 | 0.06 | 0.45 | 46\% | 69\% | 56\% | 100\% | 100\% | 29/04/2017 |  |
| Jordan | 20 | 20 | 0 | 0 | 0 | 0 | 20 | 20 | 0 | 0 | 0 | 0 | 20 | 0.00 | 0.00 | 0.33 | 100\% | 70\% | 100\% | 100\% | 25\% | 22/04/2017 |  |
| Egypt | 1413 | 1405 | 17 | 0 | 8 | 25 | 1388 | 1402 | 30 | 0 | 0 | 30 | 1372 | 0.28 | 0.34 | 1.52 | 99\% | 100\% | 100\% | 100\% | 87\% | 30/04/2017 |  |
| Kuwait | 62 | 55 | 11 | 2 | 0 | 13 | 49 | 55 | 1 | 0 | 0 | 1 | 54 | 3.58 | 0.28 | 1.32 | 92\% | 98\% | 100\% | 100\% | 7\% | 29/04/2017 |  |
| Lebanon | 79 | 47 | 19 | 12 | 21 | 52 | 27 | 26 | 0 | 0 | 1 | 1 | 25 | 9.05 | 0.00 | 0.47 | 70\% | 97\% | 68\% | 100\% | 81\% | 28/04/2017 | D8 |
| Libya | 10 | 10 | 0 | 0 | 0 | 0 | 10 | 10 | 0 | 0 | 0 | 0 | 10 | 0.00 | 0.00 | 0.17 | 100\% | 50\% | 70\% | 100\% | 70\% | 29/03/2017 |  |
| Morocco | 61 | 59 | 2 | 0 | 0 | 2 | 59 | 55 | 1 | 0 | 0 | 1 | 54 | 0.06 | 0.03 | 0.18 | 97\% | 93\% | 90\% | 100\% | 72\% | 30/04/2017 |  |
| Oman | 921 | 910 | 71 | 0 | 2 | 73 | 848 | 911 | 0 | 0 | 0 | 0 | 911 | 16.54 | 0.00 | 19.21 | 99\% | 100\% | 80\% | 100\% | 99\% | 30/04/2017 | D8, D4, B3 |
| Pakistan | 3477 | 3477 | 2157 | 0 | 0 | 2157 | 1320 | 3477 | 57 | 0 | 0 | 57 | 3420 | 12.18 | 0.32 | 0.71 | 100\% |  | 68\% | 100\% | 47\% | 30/04/2017 |  |
| Palestine | 198 | 198 | 34 | 0 | 0 | 34 | 164 | 198 | 0 | 0 | 0 | 0 | 198 | 8.16 | 0.00 | 3.93 | 100\% | 99\% | 92\% | 100\% | 98\% | 30/04/2017 | B3 |
| Qatar | 56 | 56 | 4 | 0 | 0 | 4 | 52 | 36 | 0 | 0 | 0 | 0 | 36 | 2.31 | 0.00 | 3.00 | 100\% | 100\% | 98\% | 100\% | 61\% | 27/04/2017 |  |
| Saudi Arabia | 492 | 492 | 166 | 0 | 0 | 166 | 326 | 383 | 6 | 0 | 0 | 6 | 377 | 5.85 | 0.21 | 1.13 | 100\% | 82\% | 100\% | 100\% | 96\% | 29/04/2017 |  |
| Somalia | 24 | 24 | 21 | 0 | 0 | 21 | 3 | 18 | 0 | 0 | 0 | 0 | 18 | 2.41 | 0.00 | 0.03 | 100\% |  | 21\% | 100\% | 100\% | 28/02/2017 |  |
| Sudan | 1180 | 953 | 200 | 187 | 0 | 387 | 793 | 765 | 183 | 0 | 0 | 183 | 582 | 9.40 | 4.45 | 1.48 | 96\% | 100\% | 85\% | 97\% | 96\% | 30/04/2017 |  |
| Syria | 593 | 474 | 265 | 119 | 0 | 384 | 209 | 246 | 0 | 0 | 0 | 0 | 246 | 17.14 | 0.00 | 0.93 | 100\% | 93\% | 61\% | 96\% | 93\% | 30/04/2017 |  |
| Tunisia | 67 | 62 | 1 | 0 | 0 | 1 | 66 | 65 | 3 | 0 | 0 | 3 | 62 | 0.09 | 0.28 | 0.60 | 93\% | 85\% | 48\% | 100\% | 87\% | 30/04/2017 |  |
| UAE | 167 | 156 | 28 | 0 | 13 | 41 | 126 | 143 | 5 | 0 | 1 | 6 | 137 | 4.48 | 0.55 | 1.32 | 93\% | 89\% | 94\% | 100\% | 85\% | 29/04/2017 |  |
| Yemen | 1669 | 1405 | 131 | 141 | 62 | 334 | 1335 | 1405 | 15 | 0 | 23 | 38 | 1367 | 12.00 | 0.54 | 4.74 | 92\% | 88\% | 68\% | 98\% | 12\% | 30/04/2017 |  |
| Total EMR | 14236 | 13411 | 3987 | 462 | 110 | 4559 | 9677 | 12077 | 343 | 0 | 25 | 368 | 11709 | 7.34 | 0.59 | 1.50 | 97\% | 77\% | 78\% | 99\% | 76\% |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

Countries that did not report
Djibouti

## Measles final classification and distribution by Month

Between 01/01/2017 and 30/04/2017

| Country | Total <br> Suspected <br> cases for <br> measles | Total <br> specimen <br> stested | Measlesi <br> mported <br> cases * | Measlesl <br> mport <br> related* <br> $*$ | Vaccine <br> related <br> $* * *$ |
| :--- | :---: | :---: | :---: | :---: | :---: |
| Afghanistan | 1245 | 1245 | 0 | 0 | 0 |
| Bahrain | 192 | 192 | 2 | 0 | 3 |
| Iran | 2157 | 2100 | 0 | 0 | 54 |
| Iraq | 153 | 71 | 0 | 0 | 0 |
| Jordan | 20 | 20 | 0 | 0 | 0 |
| Egypt | 1413 | 1405 | 0 | 0 | 1 |
| Kuwait | 62 | 55 | 0 | 0 | 1 |
| Lebanon | 79 | 47 | 0 | 0 | 0 |
| Libya | 10 | 10 | 0 | 0 | 0 |
| Morocco | 91 | 59 | 0 | 0 | 0 |
| Oman | 3477 | 910 | 0 | 0 | 11 |
| Pakistan | 198 | 198 | 0 | 0 | 4 |
| Palestine | 56 | 56 | 6 | 0 | 0 |
| Qatar | 492 | 492 | 0 | 0 | 4 |
| Saudi Arabia | 24 | 24 | 0 | 0 | 0 |
| Somalia | 1180 | 953 | 0 | 0 | 0 |
| Sudan | 593 | 474 | 0 | 0 | 17 |
| Syria | 67 | 62 | 0 | 0 | 0 |
| Tunisia | 167 | 156 | 0 | 0 | 0 |
| UAE | 14236 | 13411 | 8 | 0 | 95 |
| Yemen | 1405 | 0 | 0 | 0 |  |
| Total |  |  | 0 | 0 |  |
|  |  | 0 | 0 | 0 |  |


| Measles lab confirme d | Measles EpiLinked | Measles clinically comp. | Total confirme d cases \# | Jan | Feb | Mar | April | May | June | July | Aug | Sept | Oct | Nov | Dec |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 817 | 0 | 0 | 817 | 225 | 213 | 200 | 179 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 42 | 1 | 4 | 47 | 19 | 14 | 9 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 17 | 0 | 8 | 25 | 4 | 6 | 11 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 11 | 2 | 0 | 13 | 0 | 3 | 4 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 19 | 12 | 21 | 52 | 6 | 8 | 29 | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2 | 0 | 0 | 2 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 71 | 0 | 2 | 73 | 33 | 5 | 19 | 16 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2157 | 0 | 0 | 2157 | 553 | 300 | 382 | 922 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 34 | 0 | 0 | 34 | 0 | 0 | 7 | 27 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 4 | 0 | 0 | 4 | 2 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 166 | 0 | 0 | 166 | 76 | 55 | 33 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 21 | 0 | 0 | 21 | 4 | 17 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 200 | 187 | 0 | 387 | 74 | 92 | 116 | 105 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 265 | 119 | 0 | 384 | 25 | 77 | 132 | 150 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 28 | 0 | 13 | 41 | 16 | 12 | 1 | 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 131 | 141 | 62 | 334 | 81 | 120 | 97 | 36 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 3987 | 462 | 110 | 4559 | 1118 | 922 | 1044 | 1475 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

[^0]
## Cumulative geographic distribution of Measles cases in the EMR countries April 2017



## Rubella final classification and distribution by Month

Between 01/01/2017 and 30/04/2017

| Country | Total Suspected cases for rubella | Total specimen s tested | Rubella importe d* | Rubellai <br> mport <br> related <br> $* *$ | Rubella vaccine related* * * | Rubella <br> lab <br> confirme <br> $d$ | Rubella EpiLinked | Rubella clinically comp. | Total confirme d cases \# | Jan | Feb | Mar | April | May | June | July | Aug | Sept | Oct | Nov | Dec |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Afghanistan | 1245 | 423 | 0 | 0 | 0 | 36 | 0 | 0 | 36 | 8 | 7 | 13 | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bahrain | 192 | 192 | 1 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Iran | 2157 | 2100 | 0 | 0 | 54 | 4 | 0 | 0 | 4 | 0 | 1 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Iraq | 153 | 147 | 0 | 0 | 0 | 2 | 0 | 0 | 2 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Jordan | 20 | 20 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Egypt | 1413 | 1402 | 0 | 0 | 1 | 30 | 0 | 0 | 30 | 4 | 8 | 10 | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Kuwait | 62 | 55 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lebanon | 79 | 26 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Libya | 10 | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Morocco | 61 | 55 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Oman | 921 | 911 | 0 | 0 | 11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pakistan | 3477 | 3477 | 0 | 0 | 0 | 57 | 0 | 0 | 57 | 1 | 10 | 10 | 36 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Palestine | 198 | 198 | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Qatar | 56 | 36 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Saudi Arabia | 492 | 383 | 0 | 0 | 4 | 6 | 0 | 0 | 6 | 3 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Somalia | 24 | 18 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sudan | 1180 | 765 | 0 | 0 | 0 | 183 | 0 | 0 | 183 | 43 | 71 | 58 | 11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Syria | 593 | 246 | 0 | 0 | 17 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tunisia | 67 | 65 | 0 | 0 | 0 | 3 | 0 | 0 | 3 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| UAE | 167 | 143 | 0 | 0 | 0 | 5 | 0 | 1 | 6 | 2 | 2 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Yemen | 1669 | 1405 | 0 | 0 | 0 | 15 | 0 | 23 | 38 | 12 | 11 | 7 | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14236 | 12077 | 2 | 0 | 95 | 343 | 0 | 25 | 368 | 75 | 113 | 101 | 79 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

[^1]
## Cumulative geographic distribution of Rubella cases in the EMR countries April 2017



Measles and Rubella laboratory summary report
Between 01/01/2017 and 30/04/2017

| Country | Total Suspected cases M/R | Measles |  |  |  |  |  |  |  | Rubella |  |  |  |  |  |  |  | Reporte d to EPI within 4days |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | specimens tested | \% | Positive | \% | Negative | \% | Equivocal | \% | specimens tested | \% | Positive | \% | Negative | \% | Equivocal | \% |  |
| Afghanistan | 1245 | 1245 | 100\% | 821 | 66\% | 424 | 34\% | 0 | 0\% | 423 | 34\% | 37 | 9\% | 386 | 91\% | 0 | 0\% | 98\% |
| Bahrain | 192 | 192 | 100\% | 6 | 3\% | 185 | 96\% | 1 | 1\% | 192 | 100\% | 4 | 2\% | 186 | 97\% | 2 | 1\% | 99\% |
| Iran | 2157 | 2100 | 97\% | 84 | 4\% | 2015 | 96\% | 1 | 0\% | 2100 | 97\% | 21 | 1\% | 2079 | 99\% | 0 | 0\% | 93\% |
| Iraq | 153 | 71 | 46\% | 1 | 1\% | 70 | 99\% | 0 | 0\% | 147 | 96\% | 2 | 1\% | 145 | 99\% | 0 | 0\% | 100\% |
| Jordan | 20 | 20 | 100\% | 0 | 0\% | 19 | 95\% | 1 | 5\% | 20 | 100\% | 0 | 0\% | 20 | 100\% | 0 | 0\% | 25\% |
| Egypt | 1413 | 1405 | 99\% | 18 | 1\% | 1387 | 99\% | 0 | 0\% | 1402 | 99\% | 31 | 2\% | 1371 | 98\% | 0 | 0\% | 87\% |
| Kuwait | 62 | 55 | 89\% | 12 | 22\% | 43 | 78\% | 0 | 0\% | 55 | 89\% | 2 | 4\% | 53 | 96\% | 0 | 0\% | 7\% |
| Lebanon | 79 | 47 | 59\% | 19 | 40\% | 26 | 55\% | 2 | 4\% | 26 | 33\% | 0 | 0\% | 26 | 100\% | 0 | 0\% | 81\% |
| Libya | 10 | 10 | 100\% | 0 | 0\% | 9 | 90\% | 1 | 10\% | 10 | 100\% | 0 | 0\% | 8 | 80\% | 2 | 20\% | 70\% |
| Morocco | 61 | 59 | 97\% | 2 | 3\% | 56 | 95\% | 1 | 2\% | 55 | 90\% | 1 | 2\% | 53 | 96\% | 1 | 2\% | 72\% |
| Oman | 921 | 910 | 99\% | 65 | 7\% | 823 | 90\% | 22 | 2\% | 911 | 99\% | 8 | 1\% | 897 | 98\% | 6 | 1\% | 99\% |
| Pakistan | 3477 | 3477 | 100\% | 2157 | 62\% | 1320 | 38\% | 0 | 0\% | 3477 | 100\% | 57 | 2\% | 3420 | 98\% | 0 | 0\% | 47\% |
| Palestine | 198 | 198 | 100\% | 38 | 19\% | 156 | 79\% | 4 | 2\% | 198 | 100\% | 1 | 1\% | 197 | 99\% | 0 | 0\% | 98\% |
| Qatar | 56 | 56 | 100\% | 9 | 16\% | 47 | 84\% | 0 | 0\% | 36 | 64\% | 1 | 3\% | 35 | 97\% | 0 | 0\% | 61\% |
| Saudi Arabia | 492 | 492 | 100\% | 199 | 40\% | 293 | 60\% | 0 | 0\% | 383 | 78\% | 10 | 3\% | 373 | 97\% | 0 | 0\% | 96\% |
| Somalia | 24 | 24 | 100\% | 21 | 88\% | 3 | 13\% | 0 | 0\% | 18 | 75\% | 0 | 0\% | 18 | 100\% | 0 | 0\% | 100\% |
| Sudan | 1180 | 953 | 81\% | 201 | 21\% | 746 | 78\% | 6 | 1\% | 765 | 65\% | 198 | 26\% | 564 | 74\% | 3 | 0\% | 96\% |
| Syria | 593 | 474 | 80\% | 275 | 58\% | 196 | 41\% | 3 | 1\% | 246 | 41\% | 3 | 1\% | 238 | 97\% | 5 | 2\% | 93\% |
| Tunisia | 67 | 62 | 93\% | 4 | 6\% | 58 | 94\% | 0 | 0\% | 65 | 97\% | 5 | 8\% | 60 | 92\% | 0 | 0\% | 87\% |
| UAE | 167 | 156 | 93\% | 28 | 18\% | 125 | 80\% | 3 | 2\% | 143 | 86\% | 5 | 3\% | 138 | 97\% | 0 | 0\% | 85\% |
| Yemen | 1669 | 1405 | 84\% | 131 | 9\% | 1226 | 87\% | 48 | 3\% | 1405 | 84\% | 15 | 1\% | 1363 | 97\% | 27 | 2\% | 12\% |
| Total | 14236 | 13411 | 94\% | 4091 | 31\% | 9227 | 69\% | 93 | 1\% | 12077 | 85\% | 401 | 3\% | 11630 | 96\% | 46 | 0\% | 76\% |


[^0]:     the 12-23 days prior to rash onset)
    
     56 days after vaccination and there were no secondary cases identified. OR any suspect case from which virus is isolated and genotyping test reveals the virus to be a vaccine strain
    \# Total confirmed cases; include all cases confirmed by laboratory testing or epi linkage, plus those clinical cases that were reported without a laboratory specimen or epi linkage

[^1]:     the 12-23 days prior to rash onset)
    
     56 days after vaccination and there were no secondary cases identified. OR any suspect case from which virus is isolated and genotyping test reveals the virus to be a vaccine strain
    \# Total confirmed cases; include all cases confirmed by laboratory testing or epi linkage, plus those clinical cases that were reported without a laboratory specimen or epi linkage

